Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 19Neoplasm Metastasis 13Melanoma 12Nasopharyngeal Carcinoma 10Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 8Rectal Neoplasms 8Pancreatic Neoplasms 8Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Locally Advanced Rectal Cancer 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Recurrence 4Lymphoma, Extranodal NK-T-Cell 4Triple Negative Breast Neoplasms 3Sarcoma 3Nasopharyngeal Neoplasms 3Glioblastoma 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Solid Tumor 2Prostatic Neoplasms 2Lymphoma 2Lung Neoplasms 2Kidney Neoplasms 2Gastrointestinal Stromal Tumors 2

Interventions

Gemcitabine 3Albumin-Bound Paclitaxel 2spartalizumab 1canakinumab 1Taxes 1SLC-0111 1IFL protocol 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Pancreatic Ductal Adenocarcinoma × spartalizumab × Clear all
NCT04581343 2025-05-04

PanCAN-SR1

Pancreatic Cancer Action Network

Phase 1 Completed
10 enrolled 26 charts
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡